Citadel Advisors
NDRM

Citadel Advisors’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Citadel Advisors’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-341,526
Closed -$12.6M – 8588
2017
Q2 		$10.2M Buy
341,526
+216,951
+174% +$5.62M 0.01% 1445
2017
Q1 		$3.31M Buy
+124,575
New +$3.09M ﹤0.01% 2475
2015
Q1 		– Sell
-13,538
Closed -$190K – 9349
2014
Q4 		$190K Buy
+13,538
New +$107K ﹤0.01% 6034

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Citadel Advisors's NDRM Position: Q3 2017 in Review

Citadel Advisors sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2017, closing a stake of 341,526 shares — an estimated $12.6M sold.

Citadel Advisors first reported a position in NDRM in Q4 2014 and held it in 3 quarters. The position peaked at $10.2M in Q2 2017. 81 funds tracked by Wall St. Rank hold NDRM as of Q3 2017.

  • Citadel Advisors reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • Citadel Advisors sold 341,526 NeuroDerm Ltd. Ordinary Shares shares in Q3 2017, an estimated $12.6M.
  • Citadel Advisors first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2014 and held it in 3 quarters.
  • Citadel Advisors's NeuroDerm Ltd. Ordinary Shares position peaked at $10.2M in Q2 2017.
  • 81 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2017.

Based on Citadel Advisors's 13F filing for Q3 2017, filed 9 Nov 2017.